Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 23, 2020
Event Date: December 22, 2020
Context: The Company entered into a new Material Definitive Agreement (Credit Agreement) to refinance its existing debt obligations and secure future liquidity.
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than operating performance metrics (revenue, profit, cash flow). Key debt metrics include:
- New Term Loan: $40.0 million.
- New Revolving Credit Facility: $25.0 million total, comprising a $10.0 million letter of credit sub-facility and a $10.0 million swingline loan sub-facility.
- Initial Revolving Borrowings: $9.4 million drawn as of December 22, 2020.
- Maturity Date: December 22, 2025.
- Interest Rates:
- LIBOR Loans: LIBOR + 2.0% to 3.25% (subject to 0.50% floor).
- ABR Loans: Base Rate + 1.5% to 3.0% (subject to 1.0% floor).
- Unused Fee: 0.25% to 0.50% on the average daily unused revolver amount.
Material Changes Versus Prior Period
The Company replaced its prior credit facility (administered by Cerberus Business Finance, LLC) which was scheduled to expire on January 31, 2023. The new agreement resulted in the following changes:
- Payoff of Prior Debt: The Company paid off a prior term loan with an outstanding principal balance of approximately $43.9 million and a prior revolver with an outstanding balance of approximately $2.8 million.
- Financing Source: The payoff was financed entirely through borrowings under the new Credit Agreement.
- Collateral: Obligations are secured by substantially all assets of Harvard Bioscience and its guarantor subsidiaries, including equity interests in domestic and foreign subsidiaries.
- Administrative Agent: Changed from Cerberus Business Finance, LLC to Citizens Bank, N.A.
Guidance, Covenants, and Risks
Covenants: The Credit Agreement includes customary affirmative and negative covenants. Negative covenants limit the ability to incur additional debt, incur liens, make investments, sell assets, and pay dividends.
Financial Covenants: The Company must maintain a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio, tested quarterly.
Risks and Contingencies:
- Interest rates are variable and subject to market fluctuations (LIBOR or Base Rate).
- Failure to meet financial covenants could trigger an event of default.
- Prepayment is allowed without penalty, subject to LIBOR breakage and redeployment costs in certain circumstances.
Management Commentary: The filing references a press release (Exhibit 99.1) but does not contain additional narrative commentary within the text provided.
Investor Verification Checklist
- Verify the specific consolidated net leverage ratio and fixed charge coverage ratio thresholds in the Pricing Grid (Exhibit 10.1).
- Confirm the exact interest rate margin applicable to the current leverage ratio.
- Review the definition of "Consolidated Net Leverage Ratio" to understand EBITDA adjustments.
- Assess the impact of the new debt service requirements on future cash flow projections.
- Check for any subsequent amendments to the Credit Agreement or waivers of covenants.